UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RET fusions in solid tumors

Cancer treatment reviews, 2019-12, Vol.81, p.101911-101911, Article 101911

2019

Volltextzugriff (PDF)

The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future

Current treatment options in oncology, 2019-07, Vol.20 (7), p.61-61, Article 61

2019

Volltextzugriff (PDF)

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Current oncology reports, 2020-05, Vol.22 (5), p.48-48, Article 48

2020

Volltextzugriff (PDF)

Neutrophil‐Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non‐Small Cell Lung Cancer Treated with Combined Modality Therapy

The oncologist (Dayton, Ohio), 2017-06, Vol.22 (6), p.737-742

2017

Volltextzugriff (PDF)

How I treat ALK-positive non-small cell lung cancer

ESMO open, 2019, Vol.4 (Suppl 2), p.e000524-e000524, Article e000524

2019

Volltextzugriff (PDF)

Obesity Is Associated With Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.52-57

2017

Volltextzugriff (PDF)

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

European journal of cancer (1990), 2024-01, Vol.196, p.113457-113457, Article 113457

2024

Volltextzugriff (PDF)

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Clinical lung cancer, 2023-11, Vol.24 (7), p.660-665

2023

Volltextzugriff (PDF)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities-a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Translational cancer research, 2019-12, Vol.8 (Suppl 6), p.S598-S602

2019

Volltextzugriff (PDF)

Laying the Foundation for a Mesothelioma Patient Registry: Development of Data Collection Tools

International journal of environmental research and public health, 2023-03, Vol.20 (6), p.4950

2023

Volltextzugriff (PDF)

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung cancer (Amsterdam, Netherlands), 2023-12, Vol.186, p.107423-107423, Article 107423

2023

Volltextzugriff (PDF)

Immunotherapy in Lung Cancer: From a Minor God to the Olympus

Immunotherapy, 2020, Vol.1244, p.69-92

2020

Volltextzugriff (PDF)

Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.e185-e187

2019

Volltextzugriff (PDF)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

JTO clinical and research reports, 2023-12, Vol.4 (12), p.100584-100584, Article 100584

2023

Volltextzugriff (PDF)

Immunotherapy Use in Patients with HIV and Non-Small-Cell Lung Cancer: Current Data

Journal of Immunotherapy and Precision Oncology, 2019-08, Vol.2 (3), p.55-58

2019

Volltextzugriff (PDF)

Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection

Lung cancer (Amsterdam, Netherlands), 2018-09, Vol.123, p.87-90

2018

Volltextzugriff (PDF)

Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent

Clinical lung cancer, 2020-05, Vol.21 (3), p.e130-e141

2020

Volltextzugriff (PDF)

Liquid biopsy tracking of lung tumor evolutions over time

Expert review of molecular diagnostics, 2019-12, Vol.19 (12), p.1099-1108

2019

Volltextzugriff (PDF)

PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e34-e35

2024

Volltextzugriff (PDF)

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Immunotherapy, 2018, Vol.995, p.65-95

2018

Volltextzugriff (PDF)

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C -mutant non–small-cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9140-TPS9140

2023

Volltextzugriff (PDF)

Abstract PO5-18-06: On-going phase 1A clinical trial of A01, a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88) in patients with advanced malignancy

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO5-18-06-PO5-18-06

2024

Volltextzugriff (PDF)

Abstract OT3-13-01: First in Human Study of AG01 a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88)

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT3-13-01-OT3-13-01

2023

Volltextzugriff (PDF)

Abstract CT240: On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT240-CT240

2023

Volltextzugriff (PDF)

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report

Translational lung cancer research, 2020-10, Vol.9 (5), p.2149-2156

2020

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

RET fusions in solid tumors

The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Neutrophil‐Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non‐Small Cell Lung Cancer Treated with Combined Modality Therapy

How I treat ALK-positive non-small cell lung cancer

Obesity Is Associated With Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities-a commentary of the 3-year follow-up of the KEYNOTE-001 trial

Laying the Foundation for a Mesothelioma Patient Registry: Development of Data Collection Tools

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Immunotherapy in Lung Cancer: From a Minor God to the Olympus

Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

Immunotherapy Use in Patients with HIV and Non-Small-Cell Lung Cancer: Current Data

Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection

Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent

Liquid biopsy tracking of lung tumor evolutions over time

PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C -mutant non–small-cell lung cancer

Abstract PO5-18-06: On-going phase 1A clinical trial of A01, a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88) in patients with advanced malignancy

Abstract OT3-13-01: First in Human Study of AG01 a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88)

Abstract CT240: On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report

Suchergebnisse filtern